Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May 9;19(5):e0299802.
doi: 10.1371/journal.pone.0299802. eCollection 2024.

Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial

Affiliations
Randomized Controlled Trial

Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial

G Justus Hofmeyr et al. PLoS One. .

Abstract

Background: Contraceptive use has complex effects on sexual behaviour and mood, including those related to reduced concerns about unintended pregnancy, direct hormonal effects and effects on endogenous sex hormones. We set out to obtain robust evidence on the relative effects of three contraceptive methods on sex behaviours, which is important for guiding contraceptive choice and future contraceptive developments.

Methods: This is a secondary analysis of data from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) randomized trial in which 7,829 HIV-uninfected women from 12 sites in Eswatini, Kenya, South Africa and Zambia seeking contraception were randomly assigned to intramuscular depot-medroxyprogesterone acetate (DMPA-IM), the copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. Data collected for 12 to 18 months using 3-monthly behavioural questionnaires that relied on recall from the preceding 3 months, were used to estimate relative risk of post-baseline sex behaviours, as well as sexual desire and menstrual bleeding between randomized groups using modified Poisson regression.

Results: We observed small but generally consistent effects wherein DMPA-IM users reported lower prevalence of specified high risk sexual behaviours than implant users than Cu-IUD users (the '>' and '<' symbols indicate statistically significant differences): multiple sex partners 3.6% < 4.8% < 6.2% respectively; new sex partner 3.0% < 4.0% <5.3%; coital acts 16.45, 16.65, 17.12 (DMPA-IM < Cu-IUD); unprotected sex 65% < 68%, 70%; unprotected sex past 7 days 33% <36%, 37%; sex during vaginal bleeding 7.1%, 7.1% < 8.9%; no sex acts 4.1%, 3.8%, 3.4% (DMPA-IM > Cu-IUD); partner has sex with others 10% < 11%, 11%. The one exception was having any sex partner 96.5%, 96.9% < 97.4% (DMPA-IM < Cu-IUD). Decrease in sexual desire was reported by 1.6% > 1.1% >0.5%; amenorrhoea by 49% > 41% >12% and regular menstrual pattern by 26% <35% < 87% respectively.

Conclusions: These findings suggest that women assigned to DMPA-IM may have a modest decrease in libido and sexual activity relative to the implant, and the implant relative to the Cu-IUD. We found more menstrual disturbance with DMPA-IM than with the implant (and as expected, both more than the Cu-IUD). These findings are important for informing the contraceptive choices of women and policymakers and highlight the need for robust comparison of the effects of other contraceptive methods as well.

PubMed Disclaimer

Conflict of interest statement

GJH has an interest in a blood loss monitoring device which is unrelated to this paper. JMB is an employee of Gilead Sciences, outside of the present work. JD joined Pfizer after the study was completed; and was previously with FHI 360. MSM, JB, PS, KKT, RI, IB, EM, CM, JD, JS, NP, TPP, KR, MO and TDM declare no conflict of interest. There are no patents, products in development or marketed products associated with this research to declare.

Figures

Fig 1
Fig 1. Plots of sex behaviours showing relationships over time, enrollment to month 18.
Fig 2
Fig 2. Plots of side effect variables showing relationships over time, month 1 to month 18.

Similar articles

Cited by

References

    1. Both S, Lew-Starowicz M, Luria M, Sartorius G, Maseroli E, Tripodi F, et al.. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019. Nov;16(11):1681–1695. doi: 10.1016/j.jsxm.2019.08.005 - DOI - PubMed
    1. Malmborg A, Brynte L, Falk G, Brynhildsen J, Hammar M, Berterö C. Sexual function changes attributed to hormonal contraception use—a qualitative study of women experiencing negative effects. Eur J Contracept Reprod Health Care. 2020. Jun;25(3):169–175. doi: 10.1080/13625187.2020.1736545 - DOI - PubMed
    1. Malmborg A, Persson E, Brynhildsen J, Hammar M. Hormonal contraception and sexual desire: A questionnaire-based study of young Swedish women. Eur J Contracept Reprod Health Care. 2016;21(2):158–67. doi: 10.3109/13625187.2015.1079609 - DOI - PubMed
    1. Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial. Reprod Health. 2016. Apr 18;13(1):42. doi: 10.1186/s12978-016-0153-9 - DOI - PMC - PubMed
    1. Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. J Fam Plann Reprod Health Care. 2017. Jul;43(3):175–180. doi: 10.1136/jfprhc-2016-101607 - DOI - PMC - PubMed

Publication types

MeSH terms